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Background: Placental syncytiotrophoblast microvesicles (STBM) are shed into the maternal circulation during
normal pregnancy. STBM circulate in significantly increased amounts in preeclampsia (PE) and are considered to
be among contributors to the exaggerated proinflammatory, procoagulant state of PE. However, protein
composition of STBM in normal pregnancy and PE remains unknown. We therefore sought to determine the
protein components of STBM and whether STBM protein expressions differ in preeclamptic and normal
pregnancies.
Patients with PE (n = 3) and normal pregnant controls (n = 6) were recruited. STBM were prepared from placental
explant culture supernatant. STBM proteins were analyzed by a combination of 1D Gel-LC-MS/MS. Protein
expressions levels were quantified using spectral counts and validated by immunohistochemistry.
Results: Over 400 proteins were identified in the STBM samples. Among these, 25 proteins were found to be
differentially expressed in preeclampsia compared to healthy pregnant controls, including integrins, annexins
and histones.
Conclusion: STBM proteins include those that are implicated in immune response, coagulation, oxidative stress,
apoptosis as well as lipid metabolism pathways. Differential protein expressions of STBM suggest their
pathophysiological relevance in PE.
Keywords: Placental microvesicles, Pregnancy, Preeclampsia, ProteomeBackground
Microvesicles and exosomes are small (<1 μm) membrane-
bound structures generated by cells after activation or
apoptosis. They are important vehicles of intercellular
communication carrying membrane, cytosolic and nu-
clear proteins, lipids, messenger RNAs and microRNAs
[1-4]. Human placental syncytiotrophoblast microvesi-
cles (STBM) are shed into the maternal circulation in
normal pregnancy and are significantly increased in
preeclampsia (PE) [5]. STBM are proinflammatory
[6-8], procoagulant [9], and anti-angiogenic [10,11] in
normal pregnancy. Some of these characteristics are
known to be exaggerated in (PE) [9,10]; however the* Correspondence: obgmac@nus.edu.sg
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unless otherwise stated.basis of pathogenicity of preeclamptic STBM is yet to
be elucidated.
Proteomes of microvesicles derived from platelets,
plasma, malignant lymphocytes, endothelial cells, den-
dritic cells, mast cells, and intestinal epithelial cells have
been published [12-18]. Broadly, microvesicle proteins
are either ubiquitous or specific to cells of origin. Ubi-
quitous proteins are most likely involved in microvesicle
biogenesis. Examples include tetraspanins (CD9, CD63,
CD81 and CD82), heat shock proteins (HSP70, HSP90),
cytoskeletal proteins (tubulin, actin, actin binding pro-
teins), metabolic enzymes, membrane transport and
fusion proteins (annexins and RAB proteins), signal
transduction proteins (protein kinases, 14-3-3, G pro-
teins), integrins and MHC class I and II molecules [19].
Examples of cell-specific proteins include MHC class II
in exosomes from all cells expressing MHC class II, CD
86 from DC-derived exosomes (a co-stimulatory mol-
ecule for T cells), T-cell receptors for T-cell derived. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Maternal and fetal outcomes
PE (n = 3) Normal controls (n = 6)
maternal age (y) 31.[2.16]a 36.33[5.28]
Gestational age (w) 36.09[0.95] 36.38[1.56]
SBP (mm Hg) 173.25[31]*** 116.25[15.31]
DBP (mm Hg) 109.5[13.2]*** 76.5[5.58]
Proteinuria (g/24/h) 1.14[0.57] -
Infant birth wt (g) 2658[792.02] 2722.5[434.79]
Placental wt (g) 508.33[79.74] 526.80[94.17]
aResults are mean [SD], comprarisons using Student’s test (patient group, ie, PE
versus normal pregnant controls), P<0.0001***.
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on B cells, P-selectin on platelets). In contrast to exo-
somes, microvesicles released by apoptotic cells do con-
tain nuclear and organeller proteins, DNA, messenger
and microRNA. Both exosomes and microvesicles may
provide unconventional routes of protein secretion [20].
Multiple pathophysiologic factors are implicated in
adverse pregnancy outcomes such as PE, including
maternal immune maladaptation to the feto-placental
unit, excessive fetal trophoblast apoptosis, and in-
creased shedding of trophoblast debris. These result in
increased systemic inflammatory response, haemo-
static activation, endothelial dysfunction, and meta-
bolic changes [21]. Defective trophoblast invasion
resulting in abnormal uteroplacental perfusion and
oxidative stress in PE may result in qualitative and
subsequent functional changes in STBM. Quantitative
changes in serum, placental and decidual lipid and
protein oxidation products and anti-oxidant concen-
trations are significantly associated with PE [22].
Proteomic analyses of normal and PE placentas [23],
syncytiotrophoblasts [24], cytotrophoblasts [25-27],
deciduas [28], and plasmas [29,30] have been previ-
ously reported. While the role of placenta in PE is a vi-
brant area of research, the important question of why
STBM from preeclamptic placenta may have pro-
inflammatory and hypertensive effects on the maternal
systemic vasculature remain unanswered. In particular,
proteins of placental STBM in normal and preeclamp-
tic pregnancy have not been determined yet.
We hypothesized that STBM proteins are differentially
expressed in PE compared to normal pregnancies. Our
objectives were to determine protein and peptide com-
ponents of STBM that can incite pathogenic responses
in pregnancy complications and explore whether these
STBM protein expressions differ in pathologic (i.e., PE)
and normal pregnancies. As opposed to earlier studies
which employed 2D PAGE and MALDI TOF/TOF
[23,31], and 2D DIGE [29], we used 1D Gel-LC-MS/MS
approach to improve sensitivity [30]. Also, the current
study aimed to investigate protein composition of pla-
cental microvesicles in health and disease which has not
been reported to date.Results
Subject characteristics
We studied 3 pregnant women complicated with PE
and 6 healthy normal gestational age-matched preg-
nant women. The clinical characteristics of women and
maternal and neonatal outcomes are summarized in
Table 1. The patients underwent caesarean section or
vaginal delivery at gestational age >34 weeks with live
births.STBM characterization
STBM characterization data are summarized in Additional
file 1: Figure S1. H/E and immunofluorescent (PLAP)
staining of placental villous explants demonstrated the syn-
cytiotrophoblast layer (Additional file 1: Figure S1- A & B).
Scanning electron microscopy demonstrated expected size
of STBM (Additional file 1: Figure S1- C). Nanoparticle
tracking analysis [32] showed STBM size distribution
to be between 30–300 nm with a peak around 100 nm
(Additional file 1: Figure S1- D).
Identification of STBM proteins by 1D Gel-LC-MS/MS
Representative 1D gels are shown in Figure 1. After in-
gel digestion, the tryptic peptides of each gel slice were
analyzed by LC-MS/MS. Over 400 STBM proteins were
identified (Additional file 2: Table S1). Proteins were
designated as hits only when there were at least 2 unique
peptides matches and Protein Identification Probability
value of >95%. Spectral counts were used to quantify ex-
pression level of proteins in the whole lane.
Identification of differentially expressed STBM proteins in
adverse pregnancies and healthy controls
We identified 25 STBM proteins to be differentially
expressed between preeclamptic and normal pregnancies,
listed in Table 2; notable among them are annexins, integ-
rins, histones, heat shock proteins, complement regulatory
proteins, cytoskeletal proteins, and various enzymes.
Histones, integrins and CD59 glycoprotein were
downregulated while the remaining were upregulated
in preeclampsia. The Cellular components of STBM
proteins are summarized in Additional file 3: Figure S2.
Validation of proteomics results by
immunohistochemistry (IHC) analysis
IHC analysis of fixed and paraffin-embedded placental vil-
lous explants for validation of LC-MS/MS-based STBM-
proteomics data confirmed the presence of selected STBM
proteins in the syncytiotrophoblast layer at periphery
while negative controls showed no signals (Additional
file 4: Table S2, Additional file 5: Figure S3). Statistically
Figure 1 Representative 1-D SDS PAGE gel images of protein extracts from STBM. Lane 1: molecular weight marker. Lanes 2, 3 & 4: Normal
STBM. Lanes 5, 6 & 7: PE (preeclampsia) STBM. Loading Volume: 20 uL per lane (~50 ug of proteins).
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proteins, namely, histones, annexins, and integrins, could
be observed (Additional file 6: Figure S4).
Functional and pathway analysis
Ingenuity Pathways Analysis (IPA) of statistically differ-
entially expressed dataset containing 25 unique STBM
proteins identified the significant biological functions
and pathways. The major biological functions of STBM
proteins include cell death and survival, cellular assembly
and organization, immune response, lipid metabolism, and
carbohydrate metabolism (Figure 2, Additional file 7:
Table S3). The major canonical pathways include signaling
associated with glycolysis, inter-cellular junctions, integ-
rins, endothelial dysfunction (VEGF), immune response
(NF-kB and complement system) and protein ubiquitina-
tion (Figure 2, Additional file 8: Table S4).
Discussion
We sought to determine the protein composition of
STBM using 1D gel-LC-MS/MS approach to gain an
insight into the pathophysiologic changes of PE. To our
knowledge this study is the first report of STBM prote-
ome in PE in comparison to that of normal healthy
pregnancies.
Twenty five proteins were found to be differentially
expressed between STBM derived from women with
PE compared to healthy controls, including annexins,
integrins, histones, and heat shock proteins. The
annexins are calcium dependent-phospholipid binding
proteins involved in various functions including signal
transduction, stress response, inflammation, coagulation,
apoptosis and lipid metabolism. Annexin A2 has been
proposed to function inside the cell in sorting of endo-
somes and outside the cell in anticoagulant reactions [33].
The upregulation of anti-apoptosis proteins in PE STBM,such as annexin A4 (2-fold change, p < 0.05) [34], can be
explained by increased apoptotic activity of the placen-
tal syncytiotrophoblasts in PE which would trigger
the generation of anti-apoptotic proteins in an attempt
to counteract pro-inflammatory molecules such that
homeostasis is achieved. Glyceraldehyde-3-phosphate
dehydrogenase, a component of glycolytic pathway, has
important functional relevance in anaerobic glycolysis
in trophoblasts enriched in glycogen. Its increased ex-
pression in PE STBM (5-fold change, p < 0.05) could be
associated with oxidative stress that exists in these
adverse pregnancies [35,36]. Reduced expression of
complement regulatory protein such as CD59 could be
observed, suggestive of a possible role of STBM in
hemostatic activation, as well as regulation [37]. Col-
lectively all these protein expressions possibly depict
the syncytiotrophoblast response at the maternal-fetal
interface to underlying pregnancy pathology in PE.
Integrin signaling has an important role in trophoblast
invasion and vasculature remodeling [38-40]. Its down
regulation in PE STBM may be associated with shallow
trophoblast invasion and defective placental vasculature in
PE. Ezrin is involved in cell surface structure adhesion, mi-
gration and organization [41,42]. A trend towards increased
expression of proteins such as 14-3-3 proteins, annexins
and heat shock proteins may represent a protective re-
sponse to tissue injury in pathologic pregnancies [43].
Major functions of histones include DNA binding,
DNA repair and transcriptional regulation [44]. The
unique finding of downregulation of histones in PE
STBM, in this study (0.1 to 0.3-fold change, p < 0.05),
may be suggestive of defective DNA repair, increase in
damaged DNA and raised inflammatory response in
adverse pregnancies.
Interestingly, we found that STBM proteins include en-
dogenous danger molecules or alarmins which may render
Table 2 Differential protein expressions in STBM isolated from patients with PE (n = 3) versus that from pregnant
controls (n = 6)
aProtein name Symbol Accession
number
Molecular weight bMean PE cSEM PE Mean NP SEM NP p-value
isoform 1 of Annex in A2 ANXA2 IPI004553 15 39 kDa - - 66.32 16.12 -
isoform 2 of Annex in A2 ANXA2 IPI00418169 40 kDa 94.32 13.51 - - -
annex in A4 ANXA4 IPI00793199 36 kDa 109.78 24.56 47.36 9.72 0.0227
Histone H 14 HST1HiE IPI00217467 22 kDa - - 23.84 4.47 -
Histone 1.5 HST1H1B IPI00217468 23 kDa - - 6.56 169 -
Isoform 1 of Intergrin alpha-V ITGAV IPI00027505 116 kDa - - 25.60 4.02 -
Isoform Beta-1A of Intergrin beta-1 ITGB 1 IPI00217563 88 kDa 4.24 4.24 19.15 3.43 0.0353
Glyceraldehyde-3-phospahte dehydrogenase GAPDH IPI00219018 36 kDa 51.76 22.95 9.48 3.18 0.0312
Heat schock protein beta-1 HSPB IPI00025512 23 kDa 13.54 6.24 2.85 0.76 0.0398
Isoform 1 of Heat shock cognate 71 kDa protein HSPA8 IPI00003865 71 kDa 10.31 3.99 1.97 0.67 0.0202
14-3-3 protein epsillon YWHAE IPI00000816 29 kDa 11.18 3.17 - - -
Actin, cytoplasmic 1 ACTB IPI00021439 42 kDa 35.21 13.53 - - -
ADP-ribosylation factor 1 ARF 1 IPI00215914 21 kDa 6.72 2.60 - - -
Alpha-actinin-1 ACTN 1 IPI00013508 103 kDa 21.58 1.97 - - -
CD59 glycoprotein CD59 IPI00011302 14 kDa - - 9.61 2.11 -
EF-hand domain-containing protein D1 EFHD1 IPI00031091 27 kDa 5.87 3.48 - - -
Ezrin EZR IPI00843975 69 kDa 40.30 15.01 1.17 0.98 0.0056
HSPA5 protein HSPA 5 IPI00003362 72 k Da 10.80 3.96 - - -
Isoform 1 of Brain acid soluble protein 1 BASP1 IPI00299024 23 kDa 15.57 4.32 6.29 1.54 0.0373
Isoform alpha-enolase of Alpha-eno lase EN01 IPI00465248 47 kDa 12.22 6.22 1.96 0.69 0.0446
Isoform M2 of Pyruvate Kinase Isozymes MvM2 PKM IPI00479186 58 kDa 7.45 4.15 - - -
Transketo lase TKT IPI00643920 69 kDa 9.67 4.49 1.33 0.95 0.0374
Tubullin alpha-1C cahin TUBA 1C IPI00218343 50 kDa 10.24 4.47 0.33 0.33 0.0125
Tubullin beta-2C cahin TUBB4B IPI00007752 50 kDa 5.98 3.10 - - -
dTubullin, beta TUBB IPI00645452 48 kDa 6.13 3.89 - - -
aOnly proteins with a fold change >2 or <0.5 and p-value <0.05 or expressed only in one group (either PE or NP) are listed.
bNumbers represent total spectral from all the peptides of a given protein.
cResults are mean and standard error of mean (SEM), comparisons using t test between patients with preciamsia (PE n = 3) versus that from normal pregnant
conrols (NP, n = 6).
dFor complete list of all STBM proteins see Additional file 4: Table S2 in Supplementary data.
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actins, tubulins, and heat shock proteins [3]. This supports
the currently emerging role of STBM as contributors to
the pro-inflammatory state of PE.
Future biomarker discovery work will include validation
of biomarker potentials of differentially expressed proteins
in patients’ plasma. We acknowledge the limitations of
using the label-free method and spectral counts in demon-
strating the true representation of differential expression of
low abundance proteins. Confirmation of the proteins
found to be differentially expressed in this study needs to
be carried out with isotope-encoded peptides correspond-
ing to the tryptic peptides of the selected proteins. This
will help determine absolute concentration of targeted
proteins.Conclusions
The present study suggests that the biological pathways
associated with PE may include immune response,
coagulation, endothelial dysfunction as well as lipid me-
tabolism. We have recently reported differential lipid ex-
pressions in STBM from the same cohort of patients
[45]. While previous evidence for increased activation of
hemostasis and endothelial dysfunction exists, the con-
cept and proposed roles of immune-dysregulation and
lipid metabolism in pathophysiology of adverse pregnan-
cies are novel and yet to be established. Our findings are
consistent with recent reports on PE pregnancy sera
[29,30], demonstrating pro-inflammatory and lipid-
regulatory protein expressions, besides those involved in
hemostasis and endothelial dysfunction. Targeting these
Figure 2 Proposed biological network of differentially expressed proteins. Using Ingenuity Pathways Analysis software (IPA), selected
differentially expressed proteins were utilized to build a biological network based on previously reported interactions in the literature. The
expression levels of proteins were overlaid on to the network. Molecules colored with red denote upregulation and green denotes
downregulation. Finally, canonical pathways and functions were mapped on the existing network. CP: Canonical Pathway; FX: Functions.
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ment of adverse pregnancies.
Methods
Subjects and sample collection
The study subjects were patients with PE. PE was de-
fined as increased blood pressure (≥140/90 mm Hg) that
occurred after 20 wks of gestation in previously normo-
tensive women accompanied with proteinuria of ≥0.3 g/
day. The controls were gestational age-matched (within
2 gestational weeks) healthy subjects with no pregnancy
complications. Placental samples were collected at the
time of delivery and processed within 2 hours. All sam-
ples were collected from the National University Hos-
pital affiliated to the National University of Singapore,
Singapore. The research protocol was approved by the
Domain Specific Review Board.
5.2 Placental microvesicle (STBM) preparation and
characterization
Placental villous tissue (~2 gm) was cut into small pieces
(2–4) mm3 and rinsed in PBS until blood less. Explants
were cultured in 100 mm culture dishes in DMEM-F12
culture medium, supplemented with 1% antimycotic/an-
tibiotics and 10% heat-inactivated fetal bovine serum, for
generation of STBM at 37°C in 8% oxygen in the hyp-
oxic incubator (Galaxy 48R CO2 incubator with O2 con-
trol 0.1 to 19% range). Prior to addition to the culturemedia, the heat-inactivated fetal bovine serum was cen-
trifuged at 100 000 g for 60 min for removal of microve-
sicles in serum. At the end of 72 hours culture period,
the supernatant was collected followed by differential
centrifugation for isolation of STBM.
Culture supernatant was subjected to a three-step cen-
trifugation at 4°C - 1000 g for 10 min (separation of
whole cells), 10,000 g for 10 min (separation of large cel-
lular organelles, such as mitochondria, golgi, ER, etc.)
and finally, 100 000 g for 60 min (for collecting subcellu-
lar membrane microvesicles). The final pellet was col-
lected, washed in sterile PBS and resuspended in 0.5 ml
sterile PBS and stored at −20°C until use. The protein
content in each STBM preparation was quantified with
Bradford assay (Pierce, Rockford, IL). Typical STBM
preparations yielded 0.2-0.4 mg/ml vesicles. STBM size
and number in sample was determined by Nanoparticle
Tracking Analysis (NTA) method (Dragovic et al. [32]).
Finally STBM samples were subjected to evaluation scan-
ning electron microscopy (SEM). Additional 48 hr culture
of aliquots of explant culture supernatants was carried out
prior to STBM isolation to confirm the absence of bacter-
ial growth and endotoxin contamination.
Protein separation, in-gel digestion and LC-MS/MS analysis
The STBM samples prepared from placental explant cul-
ture supernatant were pelleted down. STBM pellets were
then resuspended in RIPA lysis buffer (Pierce, Rockford,
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30 minutes. The sample was centrifuged at 14,000 g for
15 minutes at 4°C and the supernatant (lysate) was
collected.
The protein lysate derived from the STBM was then
subjected to precipitation overnight at −20°C after
addition of five volumes of pre-cooled acetone. Protein
precipitation was followed by reduction with 10 mM di-
thiothreitol (DTT) and alkylation with 20 mM iodoace-
tamide (IAA). The protein content in each STBM
preparation was quantified with Bradford assay (Pierce,
Rockford, IL). Proteins (~50 μg) were separated on a
10.5-14% Tris–HCl SDS-gel (BIO-RAD) and stained
with PageBlue™ protein staining solution (Fermentas)
containing Coomassie Brilliant Blue G-250 dye. 1D SDS-
PAGE system (BIO-RAD) was used to separate the pro-
tein lysate derived from STBM.
Each lane in gel was finely cut into 13 slices, trans-
ferred into a 96 wells plate with hole and in-gel digestion
was performed as follows. First, destaining was per-
formed by the addition of 100 ul of 100 mM TEAB/
EtOH (1:1, vol/vol) and incubated with occasional vor-
texing for 60 min at 56°C, followed by addition of 100 ul
of neat acetonitrile and incubation at room temperature
with occasional vortexing, until gel pieces became white
and dried. Then acetonitrile was removed. Buffer con-
taining trypsin (20 ng/ul) was added in an amount to
cover the dry gel pieces (typically, 50 ul or more, de-
pending on the volume of a gel matrix) and left in an ice
bucket or a fridge about 15 min. After 15 min, it was
checked if all solution was absorbed and more trypsin
containing buffer was added, if necessary. After full re-
hydration the remaining trypsin buffer was spun out,
then 10–20 ul of 10 mM TEAB buffer was added to
cover the gel pieces and keep them wet during enzym-
atic cleavage. Plate with gel pieces was placed into an air
circulation thermostat and samples were incubated over-
night at 37°C. Plate was chilled to room temperature
and 5 ul 5%formic acid (FA) was added to stop digestion.
Solution was spun down into new 96 wells collection
plate using a plate centrifuge followed by addition of
50 ul 1%FA twice and 50 ul of 1:2(vol/vol) 0.1% formic
acid/acetonitrile to extract peptide from gel. 300 ul ali-
quots of the supernatant directly from the digest ex-
tracted from the gel pieces was used for the subsequent
MS/MS analysis. Samples were freeze-dried and the
dried protein film was then reconstituted in formic acid
prior to analysis by mass spectrometry.
For LC MS/MS analysis, 10 ul of 0.1% (vol/vol) formic
acid was added into each well to resuspend peptides.
5 ul sample was injected to Agilent 6538 chip LCMSMS
system for analysis after separation by Agilent 1200 LC
system, using a 1D nano -LC setup consisting of a capil-
lary pump for loading the sample (operated at 4 uL/min)onto 1.0-cm trap column and a nano pump (operated at
300 nL/min) for the separation on the analytical column.
100% water with 0.1% formic acid was used as solvent A
and 100% Acetonitrile with 0.1% formic acid was used as
solvent B. The peptides were eluted from the precolumn
using a gradient from 95% phase A (0.1% FA aqueous so-
lution) to 45% phase B (0.1% FA, 100% acetonitrile) in
60 min at 300 nl/ min directly onto an analytical column
(50-um inner diameter, 360-um outer diameter, ReproSil-
Pur C18 5um). The instrument was operated in a data-
dependent mode automatically switching between MS,
MS2. Acquisition was set to automatically select and fur-
ther fragment the fragment ion originating from the loss
of phosphoric acid from the parent ions (standard pdMS2
settings).
LC-MS/MS data processing and quantitative analysis
Generated mass spectral data were analyzed using Mascot
sequence matching software (Matrix Science). General
search parameters used were: Enzyme, Trypsin; Maximum
of 2 missed cleavages; Fixed modifications, Carbamido-
methyl (C); Variable modifications, Oxidation (M), Deami-
dated (NQ), Phospho (STY), Acetyl (K); Peptide tolerance
range ±100 ppm; and MS/MS tolerance range, ±0.6 Da.
Data import filters used were Mascot Distiller (Matrix
Science). Analyzed database-search results (.dat) from
Mascot were uploaded onto Scaffold interface. Result files
were categorized and named according to sample type or
nature. Multidimensional protein identification technology
(MuDPIT) experiment and condensation of loaded data
were selected. Proteins were designated as hits only when
there were at least 2 unique peptides matches and Protein
Identification Probability value of >95%.
The quantitation of protein expressions by spectral
counts for each identified proteins (defined as total spec-
tral counts for all the peptides of a given protein) was
carried out using Scaffold program (Proteome Software,
version 4). Only proteins with spectral counts ≥5 and a
ratio of spectral counts between two groups (patients
and normal controls) of >2 or <0.5 were tested further
by t-test and validation by immunohistochemistry.
Immunohistochemistry (IHC)
Villous explants were fixed and paraffin-embedded. Tissue
microarrays were prepared. IHC was performed according
to manufacturer’s instructions (Leica Microsystems). Briefly,
after deparaffinization and heat-induced epitope retrieval,
endogenous peroxidase blocking was performed. Slides
were incubated with primary antibodies for 45 minutes.
Antibodies used are listed in Additional file 2: Table S1.
After washing, the sections were exposed to anti-rabbit
poly-HRP-IgG in 10% animal serum for 10 minutes,
followed by DAB reagents for 3 minutes. DAB reaction
was stopped, and counterstaining with hematoxylin was
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dehydrated and finally mounted in synthetic mounting
media (Electron Microscopy Services, Hatfield, USA). Con-
trols included omission of primary antibodies. After IHC,
tissue microarray slides were scanned, analyzed and scored
(Leica Microsystems slide scanner and Slidepath image ana-
lysis software).
Functional and pathway analysis
To define biological networks, interaction and functional
analysis among the differentially expressed proteins, path-
way analyses were performed using Ingenuity Pathways
Analysis software (IPA) (Ingenuity Systems, Redwood City,
CA). Statistically differentially expressed dataset contain-
ing 25 unique proteins and their corresponding IPI identi-
fier, p-value and fold change values were uploaded into
the IPA. The significance of the connection between the
expression data and the canonical pathway were calculated
by ratio and/or Fisher’s exact.
Statistical analysis
Analysis of statistical significance of differences in pro-
tein spectral counts between patient group and normal
healthy pregnant group were sought using Student’s
two-tailed unpaired t-test. Analyzes were performed
using GraphPad Prism 5 software. Results were consid-
ered to be statistically significant if p < 0.05.
Supplementary information
Supplementary Information includes four supplementary
tables and four supplementary figures and can be found
with this article online.
Additional files
Additional file 1: Figure S1. Representative images of STBM basic
characterization. A. H/E staining of placental villous explants showing
deep blue syncytiotrophoblast (STB) layer at periphery (X20); B.
Immunofluorescence (IF) image of placental villous explants
demonstrating the bright green layer of STB stained for Placental Alkaline
Phosphatase, PLAP (X40); C. Representative scanning electron microscopy
image of STBM by (X10.000); D. Representative light scatter of STBM by
nanoparticle tracking analysis (NTA), showing STBM size to be between
30-300 nm with a peak around 100 nm.
Additional file 2: Table S1. Antibodies used for Immunohistochemistry.
Additional file 3: Figure S2. Cellular components of STBM proteins.
The placental membrane microvesicles, ie, STBM carry membrane,
cytoskeletal and regulatory proteins.
Additional file 4: Table S2. List of STBM proteins.
Additional file 5: Figure S3. Representative Immunohistochemistry
images of formalin-fixed paraffin-embedded placental villous explants
from women with preeclampsia (PE) and normal healthy pregnancy.
Proteins are localized in the syncytiotrophoblasts. Bars represent 100 μm
(original magnification X200).
Additional file 6: Figure S4. Summary of Immunohistochemical
validation of PE STBM protein expressions. Comparison of mean stainingintensity units of individual proteins in STBM from PE patients (n=3) and
normal pregnant women (n=6).
Additional file 7: Table S3. Functional analysis of the differentially
regulated proteins.
Additional file 8: Table S4. Canonical pathways predicted by Ingenuity
Pathway Analysis.
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